Scott D F, Moffett A
Epilepsia. 1986;27 Suppl 1:S42-4. doi: 10.1111/j.1528-1157.1986.tb05732.x.
Preliminary studies of patients who had brain damage, intractable epilepsy, and mental subnormality showed that clobazam in small doses (20 to 30 mg/day) was beneficial, and indicated that a more detailed investigation was worthwhile. In this study, 30 patients were followed up for at least 18 months in a continuing open-ended study. Fit frequency was found to be markedly reduced, few side effects have occurred, and the visual analogue scales and the Middlesex Hospital Questionnaire have shown improvement. "Breakthrough" has not been a problem at the dose level of 20 to 30 mg/day when given in addition to conventional anticonvulsant regimes, usually carbamazepine, phenytoin, or valproate. In the meanwhile, other psychosocial problems (for example, employment and marital problems) have improved. It therefore seems that clobazam is a useful additional drug in conventional anticonvulsant regimes.
对患有脑损伤、顽固性癫痫和智力低下的患者进行的初步研究表明，小剂量（20至30毫克/天）的氯巴占是有益的，并表明进行更详细的研究是值得的。在这项研究中，30名患者在一项持续的开放式研究中接受了至少18个月的随访。发现癫痫发作频率明显降低，很少出现副作用，视觉模拟量表和米德尔塞克斯医院问卷显示有所改善。在常规抗惊厥治疗方案（通常是卡马西平、苯妥英或丙戊酸盐）基础上加用20至30毫克/天剂量的氯巴占时，“突破性发作”并非问题。与此同时，其他社会心理问题（如就业和婚姻问题）也有所改善。因此，氯巴占似乎是常规抗惊厥治疗方案中一种有用的辅助药物。
